PSIL-006:

Lead drug candidate for

Frontotemporal Dementia

What is Frontotemporal Dementia (FTD)?

More than half of FTD patients will experience behavioral changes associated with the progression of FTD known as behavioral variant FTD (bvFTD). BvFTD is the most common form of FTD. Symptoms of bvFTD can vary, but most patients exhibit personality changes and may demonstrate a progressive decline in socially appropriate behavior.

Both FTD and bvFTD are often misdiagnosed as being other common types of neurological diseases such as Alzheimer’s. According to The Association for Frontotemporal Degeneration, on average it takes 3.6 years for patients to receive an accurate diagnosis. There are currently no approved treatment options for FTD and bvFTD.

The era of mindful medicine is here:

PSIL-006

Learn about PSIL-006 mechanism of action.

Design & Pr0mise:

PSIL-006 is a next-generation, psilocybin derivative with broad applicability and a patient-friendly profile. Because of its non-hallucinogenic profile, PSIL-006 is designed to be a good candidate for take-home use and insurability.

Preclinical Data Shows:

- PSIL-006 has demonstrated no treatment-limiting side effects, such as hallucinations.

- Animal model testing demonstrated efficacy with a single dose by reducing several symptoms commonly associated with FTD.

- PSIL-006 has demonstrated a positive effect on serotonin receptor 2A (5-HT2A) which is commonly targeted in the brain for the rapid treatment of psychiatric conditions.